• Thurs news: Novo Nordisk’s port strike distribution plan. Arcus/AZ renal cancer trial. Lilly weight loss drugs no longer in shortage. Difficulties of a CVS breakup. Google and Biontech AI lab assistants. See more on our front page

Metabolics Pathway to acknowledge call

Sadly JH nor the rest of his team can hide from the reality of the numbers. Androgel has been on a death spiral for some time now and it has aleady been communicated externally to analysts that it is expected to continue this slide. Bad press on testosterone risk, generic competition, whatever the cause(s), its going down fast,
No one in this company is immune from sales results. It wont be long now and this sales force will be going the way of cardiocare.

Nah. Jimbo says we are untouchable. Think he's got pictures on Little Ricky with a donkey.
 




Sadly JH nor the rest of his team can hide from the reality of the numbers. Androgel has been on a death spiral for some time now and it has aleady been communicated externally to analysts that it is expected to continue this slide. Bad press on testosterone risk, generic competition, whatever the cause(s), its going down fast,
No one in this company is immune from sales results. It wont be long now and this sales force will be going the way of cardiocare.

Very true.
 












Sadly JH nor the rest of his team can hide from the reality of the numbers. Androgel has been on a death spiral for some time now and it has aleady been communicated externally to analysts that it is expected to continue this slide. Bad press on testosterone risk, generic competition, whatever the cause(s), its going down fast,
No one in this company is immune from sales results. It wont be long now and this sales force will be going the way of cardiocare.

By the end of this year. They are already pushing the easy targets out with no severance.
 












Similar threads

Replies
1
Views
2K
AbbVie
anonymous
Replies
7
Views
3K
AbbVie
Anonymous
Replies
25
Views
7K
AbbVie
Anonymous
Replies
1
Views
1K
AbbVie
Anonymous